Biotech Values

[jq1234]

Key seems to be that this trial had a wide dosage variation - some doses that were too low and some that were too high. So you would get discontinuations for both efficacy and for tox. Those discontinuations in turn would drive no improvement in OS. Also, the rebound effects claimed here do not seem to have been repeated in other trials for whatever reason.

Exactly. The article just mentioned it was subset of phase 1/2, didn't give any background on the trial, and possible explanations for the issues the article raised, then just drew conclusion from 51 patients out of single arm phase 1/2 without mentioning anything of the more than 500 patients phase 3 randomized, placebo/best available therapy controlled trials.